MAPK3 and diffuse large B-cell lymphoma: These findings suggest that lenalidomide effectively inhibits DLBCL cell proliferation and invasion by modulating the CCL21/CCR7/ERK1/2 axis, highlighting its potential as a therapeutic target in DLBCL.